Q-omics provides the consensus-scored MTATP6P21 profile across patient tissues and cancer cell-line models. MTATP6P21 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MTATP6P21 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MTATP6P21 RNA expression shows 6,686 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UVM, THCA, and COAD as cancer lineages where MTATP6P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P21 survival associations across molecular data types. MTATP6P21 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P21 RNA expression–survival associations across cancer types. High MTATP6P21 expression shows unfavorable associations in UVM, KIRC, ACC, THCA and STAD, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MTATP6P21 RNA expression.
This table summarizes MTATP6P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P21 shows lower tumor expression in THCA. The THCA box plot shows higher MTATP6P21 RNA expression in normal versus tumor tissue (log2 FC = −0.064, t-test p = .005).
This table shows molecular features associated with MTATP6P21 in patient tissues and cancer cell lines. In patient samples, MTATP6P21 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
